Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients

Open access
Lu, Kan V., Zhu, Shaojun, Cvrljevic, Anna, Huang, Tiffany T., Sarkaria, Shawn, Ahkavan, David, Dang, Julie, Dinca, Eduard B., Plaisier, Seema B., Oderberg, Isaac, Lee, Yohan, Chen, Zugen, Caldwell, Jeremy S., Xie, Yongmin, Loo, Joseph A., Seligson, David, Chakravari, Arnab, Lee, Francis Y., Weinmann, Roberto, Cloughesy, Timothy F., Nelson, Stanley F., Bergers, Gabriele, Graeber, Thomas, Furnari, Frank B., James, C. David, Cavenee, Webster K., Johns, Terrance G., Mischel, Paul S.·2009·Cancer Research

Abstract

Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and short-lived. We show that the Src family kinases (SFK) Fyn and Src are effectors of oncogenic EGFR signaling, enhancing invasion and tumor cell survival in vivo. Expression of a constitutively active EGFR mutant, EGFRvIII, resulted in activating phosphorylation and physical association with Src and Fyn, promoting tumor growth and motility. Gene silencing of Fyn and Src limited EGFR- and EGFRvIII-dependent tumor cell motility. The SFK inhibitor dasatinib inhibited invasion, promoted tumor regression, and induced apoptosis in vivo, significantly prolonging survival of an orthotopic glioblastoma model expressing endogenous EGFRvIII. Dasatinib enhanced the efficacy of an anti-EGFR monoclonal antibody (mAb 806) in vivo, further limiting tumor growth and extending survival. Examination of a large cohort of clinical samples showed frequent coactivation of EGFR and SFKs in glioblastoma patients. These results establish a mechanism linking EGFR signaling with Fyn and Src activation to promote tumor progression and invasion in vivo and provide rationale for combined anti-EGFR and anti-SFK targeted therapies. [Cancer Res 2009;69(17):6889–98]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-0347

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 158

Metadata

Authors
Lu, K. V., Zhu, S., Cvrljevic, A., Huang, T. T., Sarkaria, S., Ahkavan, D., Dang, J., Dinca, E. B., Plaisier, S. B., Oderberg, I., Lee, Y., Chen, Z., Caldwell, J. S., Xie, Y., Loo, J. A., Seligson, D., Chakravari, A., Lee, F. Y., Weinmann, R., Cloughesy, T. F., Nelson, S. F., Bergers, G., Graeber, T., Furnari, F. B., James, C. D., Cavenee, W. K., Johns, T. G., & Mischel, P. S.
Venue
Cancer Research
Published
2009-08-31
Volume
69
Issue
17
Pages
6889-6898
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2171411676
Cited by
158
References
10
FWCI
7.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-0347
The paper
Lu, K. V., Zhu, S., Cvrljevic, A., Huang, T. T., Sarkaria, S., Ahkavan, D., Dang, J., Dinca, E. B., Plaisier, S. B., Oderberg, I., Lee, Y., Chen, Z., Caldwell, J. S., Xie, Y., Loo, J. A., Seligson, D., Chakravari, A., Lee, F. Y., Weinmann, R., . . . Mischel, P. S. (2009). Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-0347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.